Non-Small Cell Lung Cancer

EQRx Inc (NASDAQ: EQRX), along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-small cell lung cancer (NSCLC). The trial met the key secondary endpoint of...

The European Commission (EC) has granted conditional marketing authorization to Amgen Inc's (NASDAQ: AMGN) Lumykras (sotorasib), a KRASG12C inhibitor, for non-small cell lung cancer (NSCLC). The approval covers adult NSCLC patients with KRAS G12C mutation and who...

Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless of PD-L1 expression. Adjuvant treatment with Keytruda resulted in a statistically...

The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc's (NYSE: MRK) Keytruda for unresectable stage III or IV non-small...

CytomX Therapeutics Inc (NASDAQ: CTMX) announced preliminary Phase 2 results of CX-2029 in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC). The CD71-directed conditionally activated antibody-drug conjugate (ADC...

Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients. The trial includes patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have...

Johnson & Johnson’s (NYSE: JNJ) Janssen subsidiary has received Conditional Marketing Authorization (CMA) approval from the European Commission for Rybrevant (amivantamab) for advanced non-small cell lung cancer (NSCLC). The approval comes for activating epidermal growth...

Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus Tecentriq as an initial treatment for PD-L1-positive metastatic non-small cell lung cancer.  After 2.5 years median follow...

Blueprint Medicines Corporation (NASDAQ: BPMC) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. The deal consideration includes $250 million in cash plus $215 million in additional potential milestone payments. The acquisition includes Lengo...

The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for treating adults with a form of non-small cell lung cancer. The approval covers pralsetinib as a monotherapy for treating adults with...

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in Cohort 3B of the basket study IOV-COM-202.  The results demonstrate the feasibility of LN-145, a tumor-infiltrating...

In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib plus Merck & Co Inc’s (NYSE: MRK) Keytruda (pembrolizumab) in KRAS-mutated first-line non-small cell...

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from Phase 3 CheckMate -816 trial in patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC).  The trial evaluated Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as...

Calithera Biosciences Inc (NASDAQ: CALA) has decided to terminate its phase 2 KEAPSAKE trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. The Phase 2 KEAPSAKE study was designed to evaluate the safety and anti-tumor...

Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in a planned Phase 2a trial in non-small-cell lung cancer (NSCLC).  Under the agreement terms, Galecto will fund and...